What the pharmacist needs to know when selecting biosimilar monoclonal antibodies in oncology: the case of trastuzumab biosimilars

Thursday 23 March 2017, 15.00–16.30
Auditorium Louis Lumière

Programme
Chair: Arnold Vulto, The Netherlands

Welcome and introduction
Arnold Vulto

Selecting a biosimilar: current recommendations and future challenges
Arnold Vulto

Preparing to assess biosimilar mAbs in oncology: understanding the clinical role of trastuzumab
Marc Thill

Clinical studies for biosimilar trastuzumab in the treatment of breast cancer: similarities and differences
Liese Barbier

Call to action: panel discussion
All

Concluding comments and close
Arnold Vulto

Don’t forget to join the Synergy satellite symposium ‘10 years of biosimilars – what have we learned?’ (supported by an educational grant from Amgen) taking place on Wednesday 22 March 2017 from 11.30–13.00 in the Théâtre Claude Debussy